Kevin Shannon, MD
Professor
Pediatrics
School of Medicine

Awards

Show all (6) Hide

• Lifetime Achievement in Mentoring Award, UCSF, 2024
• UCSF Faculty Lecturer in Basic Sciences, UCSF, 2020
• Research Prize for Distinguished Contributions to Pediatric Oncology, Society of Memorial Sloan Kettering, 2019
• Research Professor Award, American Cancer Society, 2010-2020
• MERIT Award, National Cancer Institute, 2007-2017
• Roma & Marvin Auerback Distinguished Professor in Molecular Oncology, UCSF, 2000

Education & Training

Show all (3) Hide

• Post-Doc Fellow/Scholar Pediatric Hematology/Oncology UCSF 1988
• Residency Pediatrics UT Southwestern 1982
• M.D. Medicine Cornell University Medical College 1979

Grants and Projects

Show all (3) Hide

• RAF Dimer Inhibitor Treatment in Pediatric Acute Myeloid Leukemia, Alex’s Lemonade Stand Foundation, 2024-2026
• Developmental and HyperActive Ras Tumor SPORE, NIH, 2015-2026
• Selectively Targeting Oncogenic NRAS in Cancer, NIH, 2015-2026

Publications (119)

Top publication keywords:
Chromosome DeletionPrecursor T-Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteGenes, rasGenes, Tumor SuppressorMyeloproliferative DisordersHematologic Neoplasmsras ProteinsDiphenylamineNeurofibromin 1Leukemia, MyeloidLeukemiaProto-Oncogene Proteins p21(ras)Chromosomes, Human, Pair 7Lipoylation

• 5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
  Leukemia 2024 Wong JC, Weinfurtner KM, Westover T, Kim J, Lebish EJ, Del Pilar Alzamora M, Huang BJ, Walsh M, Abdelhamed S, Ma J, Klco JM, Shannon K
• Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation.
  JCI insight 2023 Chen PY, Huang BJ, Harris M, Boone C, Wang W, Carias H, Mesiona B, Mavrici D, Kohler AC, Bollag G, Zhang C, Zhang Y, Shannon K
• Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL.
  Blood advances 2023 Levinson AL, Tjoa K, Huang B, Meyer LK, Kim MO, Brady SW, Zhang J, Shannon K, Wandler AM
• ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth.
  Nature chemical biology 2021 Remsberg JR, Suciu RM, Zambetti NA, Hanigan TW, Firestone AJ, Inguva A, Long A, Ngo N, Lum KM, Henry CL, Richardson SK, Predovic M, Huang B, Dix MM, Howell AR, Niphakis MJ, Shannon K, Cravatt BF
• Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice.
  Blood 2020 Zambetti NA, Firestone AJ, Remsberg JR, Huang BJ, Wong JC, Long AM, Predovic M, Suciu RM, Inguva A, Kogan SC, Haigis KM, Cravatt BF, Shannon K

Show all (114 more) Hide

• Age-Related Ventricular Tachycardia Substrate Characteristics for Repaired Tetralogy of Fallot Before Transcatheter Pulmonary Valve Placement.
  JACC. Clinical electrophysiology 2025 Moore JP, Waldmann V, Bessière F, Babouri N, Cohen MI, O'Leary ET, Patel NS, Nazer B, Tan W, Fish FA, Dalal AS, Mariucci E, Tan RB, Lloyd MS, McLeod CJ, Anderson CC, Kanter RJ, Johnson BV, Wang B, …
• Precision Oncology for Papillary Craniopharyngioma.
  The New England journal of medicine 2023 Blakeley JO, Shannon K
• The CCDI Comes Out of the Starting Block.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Shannon K
• NFIA-ETO2, TP53, and erythroid leukemogenesis.
  Blood 2023 Huang BJ, Shannon K
• Sidestepping SHP2 inhibition.
  The Journal of experimental medicine 2023 Popescu B, Shannon K
• MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
  Neuro-oncology 2022 de Blank PMK, Gross AM, Akshintala S, Blakeley JO, Bollag G, Cannon A, Dombi E, Fangusaro J, Gelb BD, Hargrave D, Kim A, Klesse LJ, Loh M, Martin S, Moertel C, Packer R, Payne JM, Rauen KA, Rios JJ, …
• RASA2 ablation in T cells boosts antigen sensitivity and long-term function.
  Nature 2022 Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, …
• Chemical proteomic analysis of palmostatin beta-lactone analogs that affect N-Ras palmitoylation.
  Bioorganic & medicinal chemistry letters 2021 Suciu RM, Luvaga IK, Hazeen A, Weerasooriya C, Richardson SK, Firestone AJ, Shannon K, Howell AR, Cravatt BF
• KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice.
  JCI insight 2020 Wong JC, Perez-Mancera PA, Huang TQ, Kim J, Grego-Bessa J, Del Pilar Alzamora M, Kogan SC, Sharir A, Keefe SH, Morales CE, Schanze D, Castel P, Hirose K, Huang GN, Zenker M, Sheppard D, Klein OD, …
• Nf1-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK.
  Molecular cancer therapeutics 2020 Pucciarelli D, Angus SP, Huang B, Zhang C, Nakaoka HJ, Krishnamurthi G, Bandyopadhyay S, Clapp DW, Shannon K, Johnson GL, Nakamura JL
• Soil and Seed: Coconspirators in Therapy-Induced Myeloid Neoplasms.
  Blood cancer discovery 2020 Shannon K, Link DC
• Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia.
  Leukemia 2020 Wandler AM, Huang BJ, Craig JW, Hayes K, Yan H, Meyer LK, Scacchetti A, Monsalve G, Dail M, Li Q, Wong JC, Weinberg O, Hasserjian RP, Kogan SC, Jonsson P, Yamamoto K, Sampath D, Nakitandwe J, Downing …
• Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes.
  The Journal of clinical investigation 2020 Meyer LK, Huang BJ, Delgado-Martin C, Roy RP, Hechmer A, Wandler AM, Vincent TL, Fortina P, Olshen AB, Wood BL, Horton TM, Shannon KM, Teachey DT, Hermiston ML
• Subsequent Neoplasms After a Primary Tumor in Individuals With Neurofibromatosis Type 1.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Bhatia S, Chen Y, Wong FL, Hageman L, Smith K, Korf B, Cannon A, Leidy DJ, Paz A, Andress JE, Friedman GK, Metrock K, Neglia JP, Arnold M, Turcotte LM, de Blank P, Leisenring W, Armstrong GT, Robison …
• CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
  PloS one 2019 Meyer LK, Delgado-Martin C, Maude SL, Shannon KM, Teachey DT, Hermiston ML
• Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias.
  PLoS genetics 2019 Huang BJ, Wandler AM, Meyer LK, Dail M, Daemen A, Sampath D, Li Q, Wang X, Wong JC, Nakitandwe J, Downing JR, Zhang J, Taylor BS, Shannon K
• High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.
  Cell reports 2019 Mues M, Karra L, Romero-Moya D, Wandler A, Hangauer MJ, Ksionda O, Thus Y, Lindenbergh M, Shannon K, McManus MT, Roose JP
• Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer.
  Cancer cell 2018 Bielski CM, Donoghue MTA, Gadiya M, Hanrahan AJ, Won HH, Chang MT, Jonsson P, Penson AV, Gorelick A, Harris C, Schram AM, Syed A, Zehir A, Chapman PB, Hyman DM, Solit DB, Shannon K, Chandarlapaty S, …
• Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes.
  JCI insight 2018 Wong JC, Bryant V, Lamprecht T, Ma J, Walsh M, Schwartz J, Del Pilar Alzamora M, Mullighan CG, Loh ML, Ribeiro R, Downing JR, Carroll WL, Davis J, Gold S, Rogers PC, Israels S, Yanofsky R, Shannon K, …
• AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells.
  Cell stem cell 2018 Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, Pollyea DA, Smith CA, Jordan CT
• Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
  PloS one 2018 Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, Ducker GS, Matlawska-Wasowska K, Shannon K, Shokat KM, Roose JP
• Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras.
  Cold Spring Harbor perspectives in medicine 2018 Wandler A, Shannon K
• A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies.
  Cancer research 2017 Maertens O, McCurrach ME, Braun BS, De Raedt T, Epstein I, Huang TQ, Lauchle JO, Lee H, Wu J, Cripe TP, Clapp DW, Ratner N, Shannon K, Cichowski K
• KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.
  Cell 2017 Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, Firestone AJ, Young A, Lacap JA, Crocker L, Asthana S, Davis EM, Xu J, Akagi K, Le Beau MM, Li Q, Haley B, Stokoe D, Sampath D, Taylor …
• The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
  Nature medicine 2017 Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, …
• Somatic and Germline TP53 Alterations in Second Malignant Neoplasms from Pediatric Cancer Survivors.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Sherborne AL, Lavergne V, Yu K, Lee L, Davidson PR, Mazor T, Smirnoff IV, Horvai AE, Loh M, DuBois SG, Goldsby RE, Neglia JP, Hammond S, Robison LL, Wustrack R, Costello JF, Nakamura AO, Shannon KM, …
• Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.
  Haematologica 2016 Sachs Z, Been RA, DeCoursin KJ, Nguyen HT, Mohd Hassan NA, Noble-Orcutt KE, Eckfeldt CE, Pomeroy EJ, Diaz-Flores E, Geurts JL, Diers MD, Hasz DE, Morgan KJ, MacMillan ML, Shannon KM, Largaespada DA, …
• KRAS insertion mutations are oncogenic and exhibit distinct functional properties.
  Nature communications 2016 White Y, Bagchi A, Van Ziffle J, Inguva A, Bollag G, Zhang C, Carias H, Dickens D, Loh M, Shannon K, Firestone AJ
• KRAS Engages AGO2 to Enhance Cellular Transformation.
  Cell reports 2016 Shankar S, Pitchiaya S, Malik R, Kothari V, Hosono Y, Yocum AK, Gundlapalli H, White Y, Firestone A, Cao X, Dhanasekaran SM, Stuckey JA, Bollag G, Shannon K, Walter NG, Kumar-Sinha C, Chinnaiyan AM
• Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis.
  eLife 2015 Wong JC, Weinfurtner KM, Alzamora Mdel P, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen SC, Ho TT, Flach J, Reynaud D, Passegué E, Downing JR, Shannon K
• Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis.
  Nature genetics 2015 Zhao Z, Chen CC, Rillahan CD, Shen R, Kitzing T, McNerney ME, Diaz-Flores E, Zuber J, Shannon K, Le Beau MM, Spector MS, Kogan SC, Lowe SW
• CCR4 drives ATLL jail break.
  The Journal of experimental medicine 2014 Shannon KM
• Preclinical efficacy of MEK inhibition in Nras-mutant AML.
  Blood 2014 Burgess MR, Hwang E, Firestone AJ, Huang T, Xu J, Zuber J, Bohin N, Wen T, Kogan SC, Haigis KM, Sampath D, Lowe S, Shannon K, Li Q
• NRASG12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia.
  Blood 2014 Sachs Z, LaRue RS, Nguyen HT, Sachs K, Noble KE, Mohd Hassan NA, Diaz-Flores E, Rathe SK, Sarver AL, Bendall SC, Ha NA, Diers MD, Nolan GP, Shannon KM, Largaespada DA
• Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.
  Nature 2014 Dail M, Wong J, Lawrence J, O'Connor D, Nakitandwe J, Chen SC, Xu J, Lee LB, Akagi K, Li Q, Aster JC, Pear WS, Downing JR, Sampath D, Shannon K
• A(nother) RAF mutation in LCH.
  Blood 2014 Shannon K, Hermiston M
• MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.
  Cancer cell 2014 Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW
• Mutations in GATA2 are rare in juvenile myelomonocytic leukemia.
  Blood 2014 Stieglitz E, Liu YL, Emanuel PD, Castleberry RP, Cooper TM, Shannon KM, Loh ML
• Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.
  BMC cancer 2014 North M, Shuga J, Fromowitz M, Loguinov A, Shannon K, Zhang L, Smith MT, Vulpe CD
• PLC-γ and PI3K link cytokines to ERK activation in hematopoietic cells with normal and oncogenic Kras.
  Science signaling 2013 Diaz-Flores E, Goldschmidt H, Depeille P, Ng V, Akutagawa J, Krisman K, Crone M, Burgess MR, Williams O, Houseman B, Shokat K, Sampath D, Bollag G, Roose JP, Braun BS, Shannon K
• Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.
  Nature 2013 Li Q, Bohin N, Wen T, Ng V, Magee J, Chen SC, Shannon K, Morrison SJ
• Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2013 Jain N, Curran E, Iyengar NM, Diaz-Flores E, Kunnavakkam R, Popplewell L, Kirschbaum MH, Karrison T, Erba HP, Green M, Poire X, Koval G, Shannon K, Reddy PL, Joseph L, Atallah EL, Dy P, Thomas SP, …
• Pim2 is required for maintaining multiple myeloma cell growth through modulating TSC2 phosphorylation.
  Blood 2013 Lu J, Zavorotinskaya T, Dai Y, Niu XH, Castillo J, Sim J, Yu J, Wang Y, Langowski JL, Holash J, Shannon K, Garcia PD
• Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
  Cancer discovery 2013 Xu J, Haigis KM, Firestone AJ, McNerney ME, Li Q, Davis E, Chen SC, Nakitandwe J, Downing J, Jacks T, Le Beau MM, Shannon K
• Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo.
  Blood 2013 Shieh A, Ward AF, Donlan KL, Harding-Theobald ER, Xu J, Mullighan CG, Zhang C, Chen SC, Su X, Downing JR, Bollag GE, Shannon KM
• Dysregulated RasGRP1 responds to cytokine receptor input in T cell leukemogenesis.
  Science signaling 2013 Hartzell C, Ksionda O, Lemmens E, Coakley K, Yang M, Dail M, Harvey RC, Govern C, Bakker J, Lenstra TL, Ammon K, Boeter A, Winter SS, Loh M, Shannon K, Chakraborty AK, Wabl M, Roose JP
• Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.
  The Journal of clinical investigation 2012 Chang T, Krisman K, Theobald EH, Xu J, Akutagawa J, Lauchle JO, Kogan S, Braun BS, Shannon K
• Targeting oncogenic Ras signaling in hematologic malignancies.
  Blood 2012 Ward AF, Braun BS, Shannon KM
• Advancing the STATus of MPN pathogenesis.
  Blood 2012 Shah NP, Shannon K
• Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.
  Blood 2011 Xu J, Hedberg C, Dekker FJ, Li Q, Haigis KM, Hwang E, Waldmann H, Shannon K
• A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
  Science translational medicine 2011 Lyubynska N, Gorman MF, Lauchle JO, Hong WX, Akutagawa JK, Shannon K, Braun BS
• Oncogenic Ras scales the ALPS.
  Blood 2011 Shannon K, Li Q
• Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells.
  Blood 2011 Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M, Sharma T, Gavin J, Kutok JL, Iscove NN, Shannon KM, Dick JE, Neel BG, Braun BS
• Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.
  Cancer research 2011 Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO, Shannon K
• Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
  Blood 2010 Li Q, Haigis KM, McDaniel A, Harding-Theobald E, Kogan SC, Akagi K, Wong JC, Braun BS, Wolff L, Jacks T, Shannon K
• Genetics, epigenetics, and leukemia.
  The New England journal of medicine 2010 Shannon K, Armstrong SA
• Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia.
  The Journal of experimental medicine 2010 Jones L, Wei G, Sevcikova S, Phan V, Jain S, Shieh A, Wong JC, Li M, Dubansky J, Maunakea ML, Ochoa R, Zhu G, Tennant TR, Shannon KM, Lowe SW, Le Beau MM, Kogan SC
• p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.
  Genes & development 2010 Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW
• Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies.
  Blood 2010 Wong JC, Zhang Y, Lieuw KH, Tran MT, Forgo E, Weinfurtner K, Alzamora P, Kogan SC, Akagi K, Wolff L, Le Beau MM, Killeen N, Shannon K
• Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.
  Proceedings of the National Academy of Sciences of the United States of America 2010 Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, Kang HC, Kogan SC, Shokat K, Wolff L, Braun BS, Shannon K
• Proceedings from the 2009 genetic syndromes of the Ras/MAPK pathway: From bedside to bench and back.
  American journal of medical genetics. Part A 2010 Rauen KA, Schoyer L, McCormick F, Lin AE, Allanson JE, Stevenson DA, Gripp KW, Neri G, Carey JC, Legius E, Tartaglia M, Schubbert S, Roberts AE, Gelb BD, Shannon K, Gutmann DH, McMahon M, Guerra C, …
• Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras.
  Nature 2009 Lauchle JO, Kim D, Le DT, Akagi K, Crone M, Krisman K, Warner K, Bonifas JM, Li Q, Coakley KM, Diaz-Flores E, Gorman M, Przybranowski S, Tran M, Kogan SC, Roose JP, Copeland NG, Jenkins NA, Parada L, …
• Cancer: More than kin and less than kind.
  Nature 2009 Shannon K, Loh M
• The SPS affair: a complex tale of illicit proliferation.
  Cancer cell 2009 Braun BS, Shannon K
• Mutations in CBL occur frequently in juvenile myelomonocytic leukemia.
  Blood 2009 Loh ML, Sakai DS, Flotho C, Kang M, Fliegauf M, Archambeault S, Mullighan CG, Chen L, Bergstraesser E, Bueso-Ramos CE, Emanuel PD, Hasle H, Issa JP, van den Heuvel-Eibrink MM, Locatelli F, Stary J, …
• Oncogenic Kras initiates leukemia in hematopoietic stem cells.
  PLoS biology 2009 Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegué E, Shannon K, Braun BS
• Tumor suppressor gene inactivation in myeloid malignancies.
  Best practice & research. Clinical haematology 2008 Wong JC, Le Beau MM, Shannon K
• A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene.
  Blood 2008 Yin B, Delwel R, Valk PJ, Wallace MR, Loh ML, Shannon KM, Largaespada DA
• Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.
  Cancer cell 2008 Kotecha N, Flores NJ, Irish JM, Simonds EF, Sakai DS, Archambeault S, Diaz-Flores E, Coram M, Shannon KM, Nolan GP, Loh ML
• MLL5 contributes to hematopoietic stem cell fitness and homeostasis.
  Blood 2008 Zhang Y, Wong J, Klinger M, Tran MT, Shannon KM, Killeen N
• Targeting Ras in myeloid leukemias.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Braun BS, Shannon K
• Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon.
  Nature genetics 2008 Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M, Jacks T
• Mutation analysis in Costello syndrome: functional and structural characterization of the HRAS p.Lys117Arg mutation.
  Human mutation 2008 Denayer E, Parret A, Chmara M, Schubbert S, Vogels A, Devriendt K, Frijns JP, Rybin V, de Ravel TJ, Shannon K, Cools J, Scheffzek K, Legius E
• Cancer: hay in a haystack.
  Nature 2008 Shannon KM, Le Beau MM
• Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group.
  Blood 2007 Lange BJ, Smith FO, Feusner J, Barnard DR, Dinndorf P, Feig S, Heerema NA, Arndt C, Arceci RJ, Seibel N, Weiman M, Dusenbery K, Shannon K, Luna-Fineman S, Gerbing RB, Alonzo TA
• Biochemical and functional characterization of germ line KRAS mutations.
  Molecular and cellular biology 2007 Schubbert S, Bollag G, Lyubynska N, Nguyen H, Kratz CP, Zenker M, Niemeyer CM, Molven A, Shannon K
• Targeting oncogenic Ras.
  Genes & development 2007 Diaz-Flores E, Shannon K
• Hyperactive Ras in developmental disorders and cancer.
  Nature reviews. Cancer 2007 Schubbert S, Shannon K, Bollag G
• Abnormal hematopoiesis in Gab2 mutant mice.
  Blood 2007 Zhang Y, Diaz-Flores E, Li G, Wang Z, Kang Z, Haviernikova E, Rowe S, Qu CK, Tse W, Shannon KM, Bunting KD
• Deregulated Ras signaling in developmental disorders: new tricks for an old dog.
  Current opinion in genetics & development 2007 Schubbert S, Bollag G, Shannon K
• Sending out an SOS.
  Nature genetics 2007 Shannon K, Bollag G
• K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells.
  Blood 2006 Van Meter ME, Díaz-Flores E, Archard JA, Passegué E, Irish JM, Kotecha N, Nolan GP, Shannon K, Braun BS
• Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders.
  Cell cycle (Georgetown, Tex.) 2006 Kratz CP, Schubbert S, Bollag G, Niemeyer CM, Shannon KM, Zenker M
• Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo.
  Blood 2006 Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K
• Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies.
  Blood 2006 Stephens K, Weaver M, Leppig KA, Maruyama K, Emanuel PD, Le Beau MM, Shannon KM
• Inherited predispositions and hyperactive Ras in myeloid leukemogenesis.
  Pediatric blood & cancer 2006 Lauchle JO, Braun BS, Loh ML, Shannon K
• Harnessing preclinical mouse models to inform human clinical cancer trials.
  The Journal of clinical investigation 2006 Gutmann DH, Hunter-Schaedle K, Shannon KM
• Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.
  Blood 2006 Loh ML, Goldwasser MA, Silverman LB, Poon WM, Vattikuti S, Cardoso A, Neuberg DS, Shannon KM, Sallan SE, Gilliland DG
• Germline KRAS mutations cause Noonan syndrome.
  Nature genetics 2006 Schubbert S, Zenker M, Rowe SL, Böll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP
• Therapy-induced malignant neoplasms in Nf1 mutant mice.
  Cancer cell 2005 Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, Borowsky A, Horvai A, Kogan SC, Bonifas J, Huey B, Jacks TE, Albertson DG, Shannon KM
• Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
  Blood 2005 Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein I, Sievers EL
• Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22.
  Genomics 2005 Curtiss NP, Bonifas JM, Lauchle JO, Balkman JD, Kratz CP, Emerling BM, Green ED, Le Beau MM, Shannon KM
• JAKing up hematopoietic proliferation.
  Cancer cell 2005 Shannon K, Van Etten RA
• Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells.
  The Journal of experimental medicine 2005 Katsumoto TR, Duda J, Kim A, Wardak Z, Dranoff G, Clapp DW, Shannon K
• Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells.
  Blood 2005 Schubbert S, Lieuw K, Rowe SL, Lee CM, Li X, Loh ML, Clapp DW, Shannon KM
• Focus on myeloproliferative diseases and myelodysplastic syndromes.
  Cancer cell 2004 Van Etten RA, Shannon KM
• RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
  Genes, chromosomes & cancer 2004 Side LE, Curtiss NP, Teel K, Kratz C, Wang PW, Larson RA, Le Beau MM, Shannon KM
• The sum is greater than the FGFR1 partner.
  Cancer cell 2004 Braun BS, Shannon K
• Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder.
  Blood 2004 Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, Wang E, Kogan SC, Le Beau MM, Parada L, Shannon KM
• SHP-2 and myeloid malignancies.
  Current opinion in hematology 2004 Tartaglia M, Niemeyer CM, Shannon KM, Loh ML
• Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder.
  Proceedings of the National Academy of Sciences of the United States of America 2003 Braun BS, Tuveson DA, Kong N, Le DT, Kogan SC, Rozmus J, Le Beau MM, Jacks TE, Shannon KM
• Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis.
  Blood 2003 Loh ML, Vattikuti S, Schubbert S, Reynolds MG, Carlson E, Lieuw KH, Cheng JW, Lee CM, Stokoe D, Bonifas JM, Curtiss NP, Gotlib J, Meshinchi S, Le Beau MM, Emanuel PD, Shannon KM
• IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease.
  Proceedings of the National Academy of Sciences of the United States of America 2003 Wong S, McLaughlin J, Cheng D, Shannon K, Robb L, Witte ON
• Acute myeloid leukemia associated with t(8;21) or trisomy 8 in children with neurofibromatosis, type 1.
  Journal of pediatric hematology/oncology 2003 Kratz CP, Antonietti L, Shannon KM, Dole MG, Friebert SE
• Mouse cancer models as a platform for performing preclinical therapeutic trials.
  Current opinion in genetics & development 2003 Weiss B, Shannon K
• Acute leukemia: a pediatric perspective.
  Cancer cell 2002 Downing JR, Shannon KM
• Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells.
  Cancer cell 2002 Donovan S, See W, Bonifas J, Stokoe D, Shannon KM
• Testing of new agents in childhood cancer preclinical models: meeting summary.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2002 Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith…
• Hematologic effects of inactivating the Ras processing enzyme Rce1.
  Blood 2002 Aiyagari AL, Taylor BR, Aurora V, Young SG, Shannon KM
• Resistance in the land of molecular cancer therapeutics.
  Cancer cell 2002 Shannon KM
• MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia.
  Oncogene 2002 Emerling BM, Bonifas J, Kratz CP, Donovan S, Taylor BR, Green ED, Le Beau MM, Shannon KM
• Ras processing as a therapeutic target in hematologic malignancies.
  Current opinion in hematology 2002 Le DT, Shannon KM
• GTPase activating proteins: critical regulators of intracellular signaling.
  Biochimica et biophysica acta 2002 Donovan S, Shannon KM, Bollag G
• Genomic structure of the PIK3CG gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor.
  Blood 2002 Kratz CP, Emerling BM, Bonifas J, Wang W, Green ED, Le Beau MM, Shannon KM